Helvea

Type: Company
Name: Helvea
First reported 34 mins ago - Updated 34 mins ago - 1 reports

Roche Profit Falls on Franc Strength as New-Drug Sales Climb

(Updates with analyst comment in the fourth paragraph, share price in fifth.)July 24 (Bloomberg) -- Roche Holding AG, the world’s biggest maker of cancer drugs, said first-half profit fell 7 percent as the strength of the Swiss franc offset rising sales ... [Published Washington Post - 34 mins ago]
First reported Jul 22 2014 - Updated Jul 23 2014 - 1 reports

Credit Suisse quits commodities trading, cuts $8B from risk-weighted assets

14:13 ET | About: Credit Suisse Group AG (CS)Credit Suisse (CS -1.7%) says it will quit commodities trading after chalking up its biggest loss since the financial crisis in 2008, the result of a 1.6B Swiss franc ($1.78B) fine from U.S. authorities for ... [Published Seeking Alpha - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

UPDATE 2-Actelion CEO seeks to diffuse takeover talk

* Actelion rumoured as tax-driven takeover target* CEO says shareholders support its independence* Company raises full-year outlook* Q2 core earnings 233 mln Sfr vs 171 mln forecast* Shares rise 2.4 pct, outperform sector (Adds CEO quotes, details on ... [Published Reuters - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

AstraZeneca plc Given Hold Rating at Helvea (AZN)

AstraZeneca plc (LON:AZN)Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. reiterated a "buy" rating on shares of AstraZeneca plc in a research note on Wednesday, July 16th. They now have a ... [Published American Banking News - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 19 2014 - 1 reports

Novartis Joins Google To Develop Contacts For Diabetics

Development of devices and mobile applications in the health care sector has exploded of late. Now, according to The New York Times, drugmaker NovartisA Real Win For DiabeticsThe advantage of constant, non-invasive blood sugar monitoring for diabetics, ... [Published Benzinga.com - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Novartis AG (ADR) (NVS) Beats Analyst Estimates; Is Expected To Perform Well Backed By Recent Deals

In an interview with Bloomberg , Odile Rundquist, who is an analyst at Helvea, discusses on the second Qtr. results of the world’s largest drug maker by revenue, Novartis AG (ADR) (NYSE: NVS ).“I would say first that they do not really miss estimates. ... [Published InsiderMonkey.com - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Novartis Misses Estimates as Vaccine Unit Slumps

July 17 (Bloomberg) -- Novartis AG, the world’s largest drugmaker by revenue, reported second-quarter profit that missed analysts’ estimates, dragged down by declining sales and a worsening loss in the vaccine division it’s selling. Helvea Analyst Odile ... [Published Bloomberg - Jul 17 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Lindt buys No.3 slot in U.S. market with candy maker Russell Stover

By Caroline Copley and Silke KoltrowitzZURICH (Reuters) - Switzerland's Lindt & Spruengli has agreed to buy U.S. candy maker Russell Stover in a billion-dollar deal that makes it the third-biggest chocolate maker in the United States behind Hershey and ... [Published Yahoo! UK and Ireland - Jul 14 2014]
First reported Jul 02 2014 - Updated Jul 03 2014 - 1 reports

Roche to Buy Seragon for Up to $1.7 Billion for Cancer Drugs

(Updates with analyst comment in fourth paragraph.)July 2 (Bloomberg) -- Roche Holding AG, the world’s biggest maker of cancer drugs, agreed to buy Seragon Pharmaceuticals Inc. for as much as $1.7 billion to gain a new generation of experimental treatments ... [Published Washington Post - Jul 02 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

UPDATE 2-Austrian chipmaker AMS in talks to buy Germany's Dialog

* Firms say talks in "very preliminary" stage* Combined company will have about $1.4 bln annual sales* Could better tap market for web-connected devices* Dialog shares up 3.7 pct, AMS shares down 1 pct(Adds sources, analysts, background)FRANKFURT, June ... [Published CNBC - Jun 26 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Santhera CEO Seeks Licensing Partners for Drug in North America

Santhera Pharmaceuticals Holding AG (SANN) ,a Swiss drug developer whose stock has risen more than eightfoldthis year, said it attracted interest from potential licenseesto sell its Catena drug in North America.“After successful results from the Phase ... [Published Bloomberg - Jun 23 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 1 reports

Actelion racing to regulators after potential blockbuster PAH drug aces PhIII

Actelion CEO Jean-Paul ClozelShares of Switzerland's Actelion ($ATLN) spiked 15% Monday morning after the biotech reported that its next-gen oral pulmonary arterial hypertension (PAH) drug selexipag proved a success in Phase III, setting up a showdown ... [Published FierceBiotech - Jun 16 2014]

Quotes

"We are really very confident that Opsumit is not only going to be replacing but also topping Tracleer, but we must not be too impatient, it will take time" Clozel said
Rating Novartis a “BUY,” analyst Olav Zilian of Helvea wrote in a research note, "Given Alcon's leading role in the market of contact lenses, it was a smart movemove on Google's side to team up with this Novartis division to innovate this market by marrying microchip-based technology with that of a contact lens as a carrier."
"It is a billion(-dollar) deal. How much more than one billion I cannot say" Lindt Chairman and Chief Executive Ernst Tanner told Reuters in an interview on Monday
The European Medicines Agency classed Cellectis " UCART19 as an advanced-therapy medicinal product, causing the French biotech's stock to rise yet again. The 10% jump that followed the news came one week after a deal with Pfizer ( $PFE ) sent Cellectis' stock soaring. Release"

More Content

All (16) | News (14) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Roche Profit Falls on Franc Strength as New-Dru... [Published Washington Post - 34 mins ago]
Credit Suisse quits commodities trading, cuts $... [Published Seeking Alpha - Jul 22 2014]
AstraZeneca plc Given Hold Rating at Helvea (AZN) [Published American Banking News - Jul 22 2014]
UPDATE 2-Actelion CEO seeks to diffuse takeover... [Published Reuters - Jul 22 2014]
Novartis AG (ADR) (NVS) Beats Analyst Estimates... [Published InsiderMonkey.com - Jul 18 2014]
Novartis Joins Google To Develop Contacts For D... [Published Benzinga.com - Jul 18 2014]
Novartis Misses Estimates as Vaccine Unit Slumps [Published Bloomberg - Jul 17 2014]
Lindt buys No.3 slot in U.S. market with candy ... [Published Yahoo! UK and Ireland - Jul 14 2014]
Roche to Buy Seragon for Up to $1.7 Billion for... [Published Washington Post - Jul 02 2014]
Woodford buys $50M Prothena stake, Shire lacks ... [Published FierceBiotech - Jun 26 2014]
UPDATE 2-Austrian chipmaker AMS in talks to buy... [Published CNBC - Jun 26 2014]
Santhera CEO Seeks Licensing Partners for Drug ... [Published Bloomberg - Jun 23 2014]
Actelion racing to regulators after potential b... [Published FierceBiotech - Jun 16 2014]
Goodbye Biotech "Growth Bubble"; Hello Pharma "... [Published Zero Hedge - Apr 22 2014]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: Po... [Published Proactiveinvestors United Kingdom RSS feed - Apr 09 2014]
800 jobs being cut at Zurich as insurer moves t... [Published Financial Post | Business » Executive - Mar 11 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Goodbye Biotech "Growth Bubble"; Hello Pharma "... [Published Zero Hedge - Apr 22 2014]
While the rest of the market has been largely quiet as earnings week unfolds, it have been the pharma companies that has stolen the spotlight in the past few days. First it was the rumor that Pfizer may, reluctantly, be courting Astra-Zeneca, then yesterday ...
800 jobs being cut at Zurich as insurer moves t... [Published Financial Post | Business » Executive - Mar 11 2014]
Zurich Insurance Group AG, the biggest Swiss insurer, plans to save $250 million annually by cutting as many as 800 jobs after lowering its profit goal in December, the company said. Zurich plans to remove management layers between the headquarters ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.